Truqap Combination Approved in the US as First and Only Targeted Treatment for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
RegulatoryapprovedTruqapabirateroneprednisonePositive
AI Analysis
Summary
AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone received FDA approval as the first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer in adults.
Outcome Details
FDA approval as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
Importance:8/10
Sentiment:
0.90
FDA ApprovalOncologyProstate CancerFirst-in-classTargeted Therapy
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 12, 2026 8:06 PM